CClinicalTrials.gg
Enrolling by invitationNCT07444099Updated Mar 2, 2026

Early Postoperative Intervention in Gastric Cancer Patients

An interventional study of Early structured postoperative intervention encompassing nutrition, psychology, and exercise in Gastric Cancer (GC) and Postoperative Recovery, sponsored by Qilu Hospital of Shandong University. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Qilu Hospital of Shandong University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
264
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study was conducted by Qilu Hospital and five other renowned medical centers, aiming to evaluate the impact of early structured postoperative intervention on quality of life and prognosis in patients with gastric cancer after neoadjuvant therapy.

Read the detailed description

Investigators are conducting a two-arm, multicenter, interventional study at Qilu Hospital of Shandong University and five other renowned hospitals in China. A total of 264 gastric cancer patients who have completed preoperative neoadjuvant therapy will be randomly assigned to either the control group or the experimental group.For control group,patients will receive standard ERAS discharge management, including routine discharge education; outpatient follow-up visits on postoperative day 7 and postoperative day 30; and emergency contact via hospital telephone or emergency department visits for urgent situations.For experimental group,in addition to standard ERAS discharge management, patients will receive multimodal structured interventions during follow-up visits targeting nutritional status, psychological status, and exercise status. Nutritional intervention: Routine postoperative oral nutritional supplements (ONS) will be provided, and patients with metabolic diseases such as diabetes will undergo strict glycemic control. Psychological intervention: Patients with a Hospital Anxiety and Depression Scale (HADS) score ≥ 8 will receive cognitive behavioral therapy (CBT), and those with a HADS score ≥ 11 will be referred for psychological consultation. Exercise intervention: Postoperative rehabilitation training will be guided according to different postoperative periods.During the study period, the incidence of complications within 30 days postoperatively and quality of postoperative recovery were statistically analyzed, among other outcomes.

02

Conditions studied

  • Gastric Cancer (GC)
  • Postoperative Recovery

Keywords

  • gastric cancer
  • postoperative care
  • postoperative complications
  • recover quality
03

In context

Stomach Neoplasms

2,851 studies on the registry are indexed under Stomach Neoplasms; 864 are open to participants now.

This study's planned enrollment of 264 is above the median of 67 across 2,096 interventional studies indexed under Stomach Neoplasms.

Browse Stomach Neoplasms studies →

Lead sponsor

Qilu Hospital of Shandong University is the lead sponsor of 299 studies on the registry; 181 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18-80 years;
  • Histologically confirmed adenocarcinoma by preoperative pathology;
  • Completed preoperative neoadjuvant therapy without obvious immune-related adverse events (irAEs);
  • Patients with ycT3-4N+Mx disease deemed surgically resectable based on evaluation by gastroscopy, CT, PET-CT, and other imaging modalities;
  • Signed informed consent and voluntary participation in this study;
  • Standard ERAS (Enhanced Recovery After Surgery) management during the - perioperative period, with postoperative hospital stay ≤7 days.

Exclusion criteria

Exclusion Criteria:

  • Patients with central nervous system diseases or psychiatric disorders;
  • Patients with severe diseases of other organ systems;
  • Patients with recurrent infectious diseases or severe comorbidities;
  • Patients requiring synchronous surgery for other diseases;
  • Patients undergoing emergency surgery;
  • Patients who developed any complication during hospitalization.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
264 participants (estimated)

Study arms

  • Experimental
    Patients with early structured postoperative intervention

    Combination Product: Early structured postoperative intervention encompassing nutrition, psychology, and exercise

  • No intervention
    Patients without early structured postoperative intervention

Interventions

  • Combination productEarly structured postoperative intervention encompassing nutrition, psychology, and exercise

    Nutritional intervention: Routine postoperative oral nutritional supplements (ONS) will be provided, and patients with metabolic diseases such as diabetes will undergo strict glycemic control. Psychological intervention: Patients with a Hospital Anxiety and Depression Scale (HADS) score ≥ 8 will receive cognitive behavioral therapy (CBT), and those with a HADS score ≥ 11 will be referred for psychological consultation. Exercise intervention: Postoperative rehabilitation training will be guided according to different postoperative periods.

06

What researchers measure

Primary outcomes

  1. incidence of complications within 30 days postoperatively

    The incidence of complications within 30 days postoperatively was calculated as the number of patients who developed complications within 30 days after surgery divided by the total number of patients in that group.

    Time frame: 30 days after operation

  2. Postoperative recovery quality

    Postoperative recovery quality was assessed using The 15-item Quality of Recovery Score scale, with a maximum score of 150 points and a minimum score of 0 points, where higher scores indicate better postoperative recovery quality

    Time frame: Baseline (Day of Discharge) and POD 30(30 days after surgery)

Secondary outcomes

  1. Readmission or emergency department visit rate within 30 days postoperatively

    The rate of Readmission or emergency department visit within 30 days postoperatively was calculated as the number of patients who was readmitted or visited emergency department within 30 days after surgery divided by the total number of patients in that group.

    Time frame: 30 days after surgery

  2. Time interval between surgery and initiation of adjuvant chemotherapy

    The time interval was calculated as the number of days from postoperative day 1 to the start of adjuvant chemotherapy.

    Time frame: 6 month after surgery

  3. Completion rate of postoperative chemotherapy / Adherence to adjuvant chemotherapy

    The completion rate of postoperative chemotherapy was calculated as the number of chemotherapy cycles actually completed divided by the number of chemotherapy cycles planned.

    Time frame: 6 month after surgery

  4. Grading of chemotherapy-related adverse events

    It was evaluated by CTCAE version 5.0,with severity classified from Grade 1 (mild) to Grade 5 (death).

    Time frame: 6 month after surgery

  5. Postoperative quality of life score

    The EORTC Quality of Life Questionnaire for Gastric Cancer (C30 + STO22) questionaire was used to evaluate quality of postoperative recovery, all scales range from 0 to 100. For global health status, higher scores indicate better outcomes; for all functioning and symptom scales in both questionnaires, higher scores indicate worse outcomes.

    Time frame: Baseline (Day of Discharge) and POD 30(30 days after surgery)

07

Study locations

1 site
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
08

References and documents

Publications

  • Basch E. Patient-Reported Outcomes - Harnessing Patients' Voices to Improve Clinical Care. N Engl J Med. 2017 Jan 12;376(2):105-108. doi: 10.1056/NEJMp1611252. No abstract available. PubMed 28076708 ↗
  • Gillis C, Ljungqvist O, Carli F. Prehabilitation, enhanced recovery after surgery, or both? A narrative review. Br J Anaesth. 2022 Mar;128(3):434-448. doi: 10.1016/j.bja.2021.12.007. Epub 2022 Jan 7. PubMed 35012741 ↗
  • Michard F, Thiele RH, Le Guen M. One small wearable, one giant leap for patient safety? J Clin Monit Comput. 2022 Feb;36(1):1-4. doi: 10.1007/s10877-021-00767-0. Epub 2021 Oct 19. No abstract available. PubMed 34665392 ↗
  • Tian Y, Cao S, Liu X, Li L, He Q, Jiang L, Wang X, Chu X, Wang H, Xia L, Ding Y, Mao W, Hui X, Shi Y, Zhang H, Niu Z, Li Z, Jiang H, Kehlet H, Zhou Y. Randomized Controlled Trial Comparing the Short-term Outcomes of Enhanced Recovery After Surgery and Conventional Care in Laparoscopic Distal Gastrectomy (GISSG1901). Ann Surg. 2022 Jan 1;275(1):e15-e21. doi: 10.1097/SLA.0000000000004908. PubMed 33856385 ↗
  • Sauro KM, Smith C, Ibadin S, Thomas A, Ganshorn H, Bakunda L, Bajgain B, Bisch SP, Nelson G. Enhanced Recovery After Surgery Guidelines and Hospital Length of Stay, Readmission, Complications, and Mortality: A Meta-Analysis of Randomized Clinical Trials. JAMA Netw Open. 2024 Jun 3;7(6):e2417310. doi: 10.1001/jamanetworkopen.2024.17310. PubMed 38888922 ↗

Individual participant data

Plan to share: Yes — All individual participant data (IPD) underlying the published results

Supporting information: Study protocol

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07444099
Lead sponsor
Qilu Hospital of Shandong University
Collaborators
Linyi People's Hospital, Liaocheng People's Hospital, Yantai Yuhuangding Hospital, Central Hospital of Zibo, Weifang People's Hospital
Responsible party
Qu Hui (Chief Physician, Qilu Hospital of Shandong University) — Principal investigator
First posted
Mar 2, 2026
Start date
Feb 10, 2026
Primary completion
Mar 10, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Mar 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion